QGEN - Rasio rega marang pendapatan Qiagen Corp
The price-to-sales ratio illustrates the valuation dynamics of Qiagen N.V. (QGEN), where the value 4.90 describes the current status of the metric. Stable demand for diagnostic systems and DNA analysis kits ensures a predictable cash inflow. A global distribution network across Europe and the US supports high profitability. The lock-in of laboratories to the brand's consumables guarantees sustainable profit generation.
Rincian analitis perusahaan Qiagen NV (QGEN)
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- statistik nilai buku emiten:
- rincian struktur utang lan likuiditas bisnis:
Rasio Utang marang Modal Qiagen N.V.|QGEN - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal qiagen.com|QGEN - Utang perusahaan|Rasio utang marang nilai buku Qiagen Corp|QGEN - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Qiagen|Rasio likuiditas darurat qiagen.com
- data bathi resik lan rasio valuasi:
QGEN - Bathi resik|Proyeksi bathi mangsa ngarep Qiagen N.V.|QGEN - Rasio rega marang bathi|Pangali forward rega marang bathi Qiagen Group|QGEN - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Qiagen Corp|QGEN - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Qiagen|QGEN - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham sajroning taun lumaku qiagen.com|QGEN - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Qiagen N.V.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:Qiagen (QGEN)
The P/S multiple determines the market value of a business relative to its annual turnover, allowing an investor to assess the premium paid per unit of generated revenue. For Qiagen N.V. (QGEN), whose diagnostic systems are integrated into the global laboratory network, analyzing the price-to-sales multiple helps align market capitalization with the actual scale of equipment sales, revealing whether the asset is fundamentally undervalued or overheated.
Perusahaan pesaing
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Ionis Pharma IONS|RGEN - Kapitalisasi marang pendapatan|RNA - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Rasio rega marang pendapatan|Rasio rega marang dodolan RARE (Ultragenyx)|Kapitalisasi marang pendapatan BEAM|Multiplikator P/S Sarepta Corp|Rasio rega marang pendapatan Twist Bioscience, Inc. (TWST)|Kapitalisasi marang pendapatan 10x Genomics TXG|Rasio rega marang pendapatan Intellia Therapeutics NTLA|Kapitalisasi marang volume dodolan STOK (Stoke Therapeutics, Inc.)|BLFS - Rasio rega marang pendapatan|Rega marang dodolan Wave Pharma|mazetx.com (MAZE) - Rasio rega marang pendapatan|SION - Koefisien rega marang pendapatan|PRME (Prime Medicine Inc) - Multiplikator P/S|Taysha Gene Therapies, Inc. - Rasio rega marang dodolan|Multiplikator P/S QURE|MGTX: Rasio rega marang dodolan|Rasio rega marang pendapatan REGENXBIO RGNX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
